Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis. - Wikidata - wikimedia - TriplyDB

Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.

Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.

http://www.wikidata.org/entity/Q38550285

about

NAFLD and Chronic Kidney Disease Comparative Effectiveness of Biologic Therapy Regimens for Ankylosing Spondylitis: A Systematic Review and a Network Meta-Analysis A Review of Western and Traditional Chinese Medical Approaches to Managing Nonalcoholic Fatty Liver Disease.Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease.Medical Management of Diabesity: Do We Have Realistic Targets?Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis.Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options.Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation The pharmacological management of NAFLD in children and adolescents.Stable isotope-based flux studies in nonalcoholic fatty liver disease.The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans.Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis.Emerging and future therapies for nonalcoholic steatohepatitis in adults.Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.NAFLD and diabetes mellitus.Thiazolidinediones for nonalcoholic steatohepatitis: A meta-analysis of randomized clinical trials.Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes.Repurposing Pentoxifylline for the Treatment of Fibrosis: An Overview.Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.Liraglutide's use in treatment of non-alcoholic fatty liver: an evaluation of the non-alcoholic steatohepatitis study.Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study.The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice Nonalcoholic fatty liver disease: Evolving paradigms.Treatment options for alcoholic and non-alcoholic fatty liver disease: A review.Drug-related covariates should be considered in Bayesian network meta-analysis of pharmacological interventions.Non-alcoholic Fatty Liver Disease: A Clinical Update.Clinical relevance of liver histopathology and different histological classifications of NASH in adults.Inhibition of MD2-dependent inflammation attenuates the progression of non-alcoholic fatty liver disease.Pioglitazone suppresses inflammation and fibrosis in nonalcoholic fatty liver disease by down-regulating PDGF and TIMP-2: Evidence from in vitro study.Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice.Clinical risk scoring for predicting non-alcoholic fatty liver disease in metabolic syndrome patients (NAFLD-MS score).2-Hydroxy-4-methoxy benzoic acid attenuates the carbon tetra chloride-induced hepatotoxicity and its lipid abnormalities in rats via anti-inflammatory and antioxidant mechanism.Pharmacotherapy of nonalcoholic steatohepatitis: Reflections on the existing evidence.The liver in focus.Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease

P2860

Q26752759-E19085FB-A99B-44F2-90B0-92CA751B44CC Q26764820-65C3D912-A9AA-462E-98C0-F52A9C21CD3C Q28074377-9BC508EC-F48F-42FB-B30F-DAB7AC172D39 Q28589784-5D8714E0-A13A-4764-977E-E6911B98957E Q30235846-72FDC8B2-F293-43AE-A571-4039E0B9512B Q30238940-EC6ACB02-D138-441F-9F64-00CBF8698D4C Q30248535-01FCE13B-179B-4567-8777-B3293E27DAFC Q33855157-B2920A8B-5BA0-4FE3-A178-F33653AF99CD Q36138443-842AE153-F3F6-4E3C-A299-07687EC82521 Q37244257-BB82DCA6-0158-45B3-B172-03DA4985BE3E Q38643266-059C65B9-BFFD-483D-8D22-4CF628DF07DC Q38655651-9C290E16-70D6-46C6-92EE-C4B10BB5E36A Q38752520-4AEFFF70-23A9-480C-8BED-4B4D7BC2B012 Q38802973-9000728D-5F9A-49A8-ADBC-EC6385C2517B Q38827586-0E468E26-217E-4109-A94A-DC2FE820C623 Q38867031-D9A70F2D-A6EF-4F5A-80E5-80E9160E3CF6 Q38978347-839035C6-14C5-48FC-9215-F083A020902F Q38985320-66DB9310-28C5-4F32-AB8A-42DE3D05EDCD Q39170225-B9821B60-F2DB-40D7-8CF7-BAFA67E6CA9E Q39292948-53906C82-5B38-4A3E-9E32-1E1A36BA55B7 Q39445103-B3BC9A03-C618-45DB-BDDC-880B813D7E75 Q40921956-5E56DC59-542B-49F9-843C-54CC863E64EB Q41623607-BE967A72-0EE5-4857-8D1B-9172D4E5D358 Q41876453-B781B828-347F-424A-82AB-F01E60806D34 Q42695154-6649E1DB-D244-47F3-B09F-038912FB7975 Q42695159-D11C55E5-8A71-45E1-97B2-0EEEC3D34540 Q43432392-7F4182C0-1BD4-41C8-8CD9-884F51FCC1EC Q47100244-C0017C36-99EB-42F8-89F6-5A6CF5335EEF Q47581786-BEE020A8-E077-4EF3-8144-67314476D249 Q47595575-AA208036-F654-4458-BD15-932E1115E7BA Q47746064-9C5B8802-3957-4F99-AB80-7D2531759DCD Q47958825-3C6B24EB-BE32-478C-B453-A98A959A8F9B Q48127172-21B4C03E-396A-4C60-A7F6-BB243D3278A5 Q48354036-C728BDD3-34DF-463E-AF3F-9CBADE08AD86 Q48359399-AFA3487F-178E-4F6F-B208-05A1B455C36E Q53790745-19F2835C-7876-4862-A4F6-BB7B0782BB4B Q57066927-BD8193A7-5CBD-4C65-8DF1-5B0E9DE76782 Q58740258-77DD90CE-3C02-4BA8-9A26-93D4AF4D8794

P2860

Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.

http://www.wikidata.org/entity/Q38550285

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Comparative effectiveness of p ...... iew and network meta-analysis.

@en

type

label

Comparative effectiveness of p ...... iew and network meta-analysis.

@en

prefLabel

Comparative effectiveness of p ...... iew and network meta-analysis.

@en

P1433

Q38550285-9050470D-0850-41A5-8209-E73A24A75BA8

P1476

Q38550285-49FC9275-B069-4E0D-8810-6292A06C9721

P2093

Q38550285-2CE79980-2BEC-4190-9592-784ED56EC835

Q38550285-6C733237-AC5D-4A22-BA47-AD2E68AE43BE

Q38550285-EB20DCD9-584B-40AB-99AC-A043D74571FE

Q38550285-EE861395-90C8-4A47-8DFF-EA8F94CE763C

P2860

Q38550285-04022EBF-4BBB-4B88-A701-D276EBF30581

Q38550285-0AF4EA3E-595F-4BA4-B2FD-814D4F10AA56

Q38550285-0BBB9C94-97AD-4BAE-B26A-B21EC3312393

Q38550285-0C6F0F11-3CD8-4A25-8C98-26B025865A19

Q38550285-16C4049B-EAF7-43BB-8F90-14B8E869E326

Q38550285-1A737E1F-6D6A-4F27-9251-1E534248A1B1

Q38550285-1E299E93-0C51-4193-9877-16AB886EBA40

Q38550285-2E6FB451-18ED-430A-9B88-BC50CE416A7A

Q38550285-3264EF25-C092-4090-8582-81F102B6A31F

Q38550285-32B99494-59C3-4D11-9E54-92277EDF1EF2

P304

Q38550285-8E6CDE17-074E-4195-888F-67091125489A

P31

Q38550285-AE5020E4-1B25-4A47-8E1D-5295D6E33619

Q38550285-ef67c3c9-0a89-4595-b480-3630ce46abfd

P356

Q38550285-CBC3B0BD-9F56-4331-BCDA-F12E316CE669

P407

Q38550285-0CB94441-0C38-4BD8-B3E4-B67E495E1B36

P433

Q38550285-AB73D111-64C1-4DD3-95FF-994DCA940ADB

P478

Q38550285-4F47A2F0-926F-4249-A587-A7DE3A60952B

P50

Q38550285-3D56C4A9-E051-4732-8E8E-09D45CAE1B70

P577

Q38550285-B7A402BA-3425-4CF6-B76B-2CA7AFFB7A8C

P698

Q38550285-94AC170D-8336-4689-B2C5-A804C31F0B09

P921

Q38550285-60903824-5F20-4815-B6C0-99158AF9DB1B

P356

P1433

P1476

Comparative effectiveness of p ...... view and network meta-analysis

@en

P2093

Alina M Allen

http://www.w3.org/2001/XMLSchema#string

M Hassan Murad

http://www.w3.org/2001/XMLSchema#string

Rohit Loomba

http://www.w3.org/2001/XMLSchema#string

Siddharth Singh

http://www.w3.org/2001/XMLSchema#string

P2860

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

Bias in meta-analysis detected by a simple, graphical test

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Measuring inconsistency in meta-analyses

Meta-analysis in clinical trials

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

Pentoxifylline downregulates profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

Combination of direct and indirect evidence in mixed treatment comparisons

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

P304

1417-1432

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.27999

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

62

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26189925

http://www.w3.org/2001/XMLSchema#string

P921

Steatohepatitis